A Study of Mosliciguat in PH-ILD
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.
Also called NCT06635850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 135 participants
- Sponsor
- Pulmovant, Inc.
- Registry
-
NCT06635850
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Japan, Latvia, Mexico, Netherlands, New Zealand, Poland, South Korea, Spain, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06635850. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-29 (actual); primary completion 2026-05-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Mosliciguat in PH-ILD
- Acronym
- PHocus
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Condition
- Lung Diseases
- Condition
- Vascular Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Fibrosis
- Intervention (Drug)
- Mosliciguat
- Intervention (Device)
- Dry Powder Inhaler
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pulmovant, Inc.
Record details
- Record id
cardio:ct-nct06635850- Content hash
602004adeb98a1fe007530e51413d42ca61f08535484f3614e3d927f0cd15c3d